Asked by: Feryal Clark (Labour - Enfield North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve treatment for individuals aged over 65 with low blood pressure in (a) Enfield North constituency, (b) the London Borough of Enfield, and (c) London.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Integrated care boards in London are responsible for arranging healthcare services that meet the needs of their local populations, including for patients over the age of 65 years old in the Enfield North Constituency, the London Borough of Enfield, and London.
The NHS Health Check, offered every five years to eligible people aged 40 to 74 years old, aims to prevent heart disease, stroke, type 2 diabetes and kidney disease, and some cases of dementia. People can also now have their blood pressure tested in many community pharmacies and over 7,500 pharmacies have delivered nearly two million blood pressure checks in just over two years, and we are working with NHS England to expand this service by investing up to £50 million over this and next year. In both services people will be referred to their general practice for further assessment and clinical treatment if required, including those with low blood pressure. Further information on the management of hypotension, low blood pressure, is available at the following website:
https://www.nhs.uk/conditions/low-blood-pressure-hypotension/
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of trends in the level of people diagnosed with Alzheimer's in the last 10 years.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
Whilst no formal assessment has been made, we know that the number of people with dementia has increased. The latest dementia diagnosis rate reported by NHS England for the end of January 2024 was 64.4%.
A table showing the number of people with a primary diagnosis of Alzheimer’s each year from 2016 to 2023, as data is not available before 2016, broken down by the type and stage of the diagnosis is attached.
Asked by: Kate Osamor (Independent - Edmonton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Government is on target to double dementia funding by 2024/25.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Government is dedicated to supporting research into dementia, and has committed to doubling the funding for dementia research to £160 million per year by the end of 2024/25. The Government’s responsibility for delivering dementia research is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science Innovation and Technology, with research delivered via UK Research and Innovation.
In 2022/23, the most recent year we have data for, we estimate that total Government spend on dementia research was £96.9 million. Spend is dependent on the number and quality of applications received, as well as the volume of research that requires infrastructure support, therefore research spend can only be calculated retrospectively after the end of the financial year.
The Government is making significant progress towards meeting the commitment and has instigated momentous new programmes of work, for instance investing almost £50 million over five years into the NIHR’s Dementia Translational Research Collaboration Trial Network, which will expand the United Kingdom’s early phase clinical trial capabilities in dementia, speeding up the development of new treatments. A new Clinical Trials Delivery Accelerator focused on dementia was also announced in the Autumn Statement 2023, with up to £20 million of funding to help innovation reach National Health Service patients even faster. Many new initiatives and research projects will begin to spend in 2024/25.
Asked by: Kate Osamor (Independent - Edmonton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how the additional £95 million investment in dementia care has been allocated.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Dame Barbara Windsor Dementia Mission was launched in August 2022 with £95 million of Government funding. There is now more than £120 million of committed funding to the mission, which will be invested into three key pillars. The first pillar centres on biomarkers and experimental medicine, and will receive £50 million of the funding for the mission, with the intention of securing match funding from industry partners. As part of this pillar, Innovate UK launched a Small Business Research Initiative competition, with the aim of accelerating innovations in clinical biomarker tools and technologies for dementia, where organisations could apply for a share of £6 million of funding out of the allocated £50 million. These technologies will enable the discovery, validation, and implementation of a suite of decision-enabling biomarkers to help transform clinical trials and precision therapies. The competition closed on 4 September 2023, and the recipients awarded a portion of the £6 million will be announced soon.
The second pillar will focus on clinical trial infrastructure and innovation, with two recently announced initiatives to support its delivery. The first of these initiatives is the National Institute for Health and Care Research’s Dementia-Translational Research Collaboration Trials Network, with almost £50 million of funding over five years. This will expand the United Kingdom’s early phase clinical trial capabilities for dementia, speeding up the development of new treatments. The second initiative is the Clinical Trials Delivery Accelerator, focused on dementia, also named the Dementia Accelerator. This was announced in the Autumn Statement 2023, in response to Lord O’Shaughnessy’s independent review into commercial clinical trials in the UK, with up to £20 million of additional funding.
The third pillar will be focused on end-to-end implementation, specifically on aligning translational research, clinical practice, and regulatory frameworks to prepare health-systems for new dementia medicines. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, NHS England, the Department, the devolved administrations, and the Dame Barbara Windsor Dementia Mission are already working closely together to plan for the implementation of new dementia medicines, should they gain approval in the UK.
Asked by: Lord Weir of Ballyholme (Democratic Unionist Party - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they will take to ensure that the cognitive and behavioural needs of dementia sufferers are properly reflected when deciding Continuing Health Care funding.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
In England, eligibility for NHS Continuing Healthcare (CHC) is not determined by age, diagnosis or condition, or financial means. It is assessed on a case-by-case basis considering the totality of an individual’s needs, including ways in which these needs interact with one another.
When an individual is identified as potentially eligible for CHC, the National Framework for NHS Continuing Healthcare and NHS Funded Nursing Care sets out the process for determining whether they have a ‘primary health need’. This includes assessment by a multidisciplinary team using a tool that has been developed to identify an individual’s needs and aid consistent decision making. A copy of the framework is attached.
Asked by: Julian Sturdy (Conservative - York Outer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help support people with early onset dementia.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
NHS England is committed to delivering high quality care and support for every person with dementia at every age, and central to this is the provision of personalised care. Provision of dementia health care services is the responsibility of local integrated care boards (ICBs). NHS England would expect ICBs to commission services based on local population needs.
The Dementia Well Pathway includes diagnosing well, living well, supporting well, and dying well, and highlights that services need to be integrated, commissioned, monitored, and aligned with the National Institute for Health and Care Excellence’s (NICE) standards for each component of the pathway. It makes it clear that individual needs, wishes and preferences should be taken into account in planning and providing care.
In January 2023 the Government announced that it will publish a Major Conditions Strategy early 2024. By bringing dementia and other conditions strategies together, we will be able to focus on where there are similarities in approach and ensure care is better centred around the patient.
Asked by: Rachel Hopkins (Labour - Luton South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how the £95 million investment in dementia clinical (a) trials and (b) innovative research will be allocated across the Mission’s pillars of (i) innovations in biomarkers, data and digital and imaging technologies, (ii) increasing the number and speed of UK-based clinical trials for research into dementia and neurodegeneration and (iii) end-to-end implementation.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Dame Barbara Windsor Dementia Mission was launched in August 2022 with £95 million of Government funding. There is now more than £120 million of committed funding to the mission, which will be invested into three key pillars. The first pillar centres on biomarkers and experimental medicine, and will receive £50 million of the funding for the mission, with the intention of securing match funding from industry partners. As part of this pillar, Innovate UK launched a Small Business Research Initiative competition, with the aim of accelerating innovations in clinical biomarker tools and technologies for dementia, where organisations could apply for a share of £6 million of funding out of the allocated £50 million. These technologies will enable the discovery, validation, and implementation of a suite of decision-enabling biomarkers to help transform clinical trials and precision therapies. The competition closed on 4 September 2023, and the recipients awarded a portion of the £6 million will be announced soon.
The second pillar will focus on clinical trial infrastructure and innovation, with two recently announced initiatives to support its delivery. The first of these initiatives is the National Institute for Health and Care Research’s Dementia-Translational Research Collaboration Trials Network, with almost £50 million of funding over five years. This will expand the United Kingdom’s early phase clinical trial capabilities for dementia, speeding up the development of new treatments. The second initiative is the Clinical Trials Delivery Accelerator, focused on dementia, also named the Dementia Accelerator. This was announced in the Autumn Statement 2023, in response to Lord O’Shaughnessy’s independent review into commercial clinical trials in the UK, with up to £20 million of additional funding.
The third pillar will be focused on end-to-end implementation, specifically on aligning translational research, clinical practice, and regulatory frameworks to prepare health-systems for new dementia medicines. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, NHS England, the Department, the devolved administrations, and the Dame Barbara Windsor Dementia Mission are already working closely together to plan for the implementation of new dementia medicines, should they gain approval in the UK.
Asked by: Claire Hanna (Social Democratic & Labour Party - Belfast South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to her Department's Press Release entitled, Prime Minister launches Dame Barbara Windsor Dementia Mission, published on 14 August 2022, how much and what proportion of the funding made available through that mission will be spent in each region.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The £95 million of Government funding allocated to the Dame Barbara Windsor Dementia Mission will be accessible across the United Kingdom, however we cannot at this stage confirm a regional breakdown of the spending allocation.
Asked by: Theresa Villiers (Conservative - Chipping Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England about improving training for NHS workers on caring for people with dementia.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
We want all relevant staff to have received appropriate training to provide high quality care to people with dementia, whether in hospital or in the community.
Individual employers are responsible for ensuring their staff are trained and competent to carry out their role, and for investing in the future of their staff through providing continuing professional development (CPD) funding.
To supplement local employer investment for CPD, the NHS Long Term Workforce Plan, published on 30 June 2023, sets out NHS England’s commitment to continue national CPD funding for nurses and allied health professionals.
There are a variety of resources available on the NHS England E-learning for Health platform, including a programme on dementia care, designed to enhance the training and education of the health and social care workforce.
Asked by: Stephen Kinnock (Labour - Aberavon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) increase capacity and (b) improve infrastructure in the NHS to help tackle dementia.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
In 2019 we committed to doubling funding for dementia research, to £160 million per year by 2024/25. This will span all areas of research from causes and prevention to treatment and care, delivering evidence to help prevent, diagnose and treat dementia, enabling the best possible care and quality of life for people with dementia.
NHS England are assessing the additional scanning, treating and monitoring capacity which would be required if potential new Alzheimer’s treatments are approved and determined to be both cost and clinically effective. This includes securing additional diagnostic capacity, for instance through magnetic resonance imaging, lumbar puncture, and positron emission tomography and computed tomography.